Barclays PLC Raises Stock Holdings in Option Care Health, Inc. (NASDAQ:OPCH)

Barclays PLC boosted its stake in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 37.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 426,532 shares of the company's stock after purchasing an additional 116,338 shares during the quarter. Barclays PLC owned about 0.25% of Option Care Health worth $9,895,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of OPCH. Granite Investment Partners LLC purchased a new stake in shares of Option Care Health during the 4th quarter valued at $7,052,000. Sterling Capital Management LLC increased its stake in Option Care Health by 638.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,954 shares of the company's stock valued at $69,000 after acquiring an additional 2,554 shares during the last quarter. Whetstone Capital Advisors LLC purchased a new stake in Option Care Health during the fourth quarter valued at about $815,000. Raymond James Financial Inc. bought a new stake in Option Care Health during the fourth quarter worth about $2,027,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Option Care Health by 2,032.6% in the 4th quarter. Renaissance Technologies LLC now owns 330,546 shares of the company's stock worth $7,669,000 after purchasing an additional 315,046 shares in the last quarter. 98.05% of the stock is currently owned by institutional investors.

Option Care Health Stock Performance

Option Care Health stock opened at $31.54 on Wednesday. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77. The firm has a market cap of $5.18 billion, a P/E ratio of 26.50, a P/E/G ratio of 2.30 and a beta of 1.07. Option Care Health, Inc. has a 1-year low of $21.39 and a 1-year high of $35.53. The firm has a 50-day moving average of $33.31 and a 200-day moving average of $28.68.

Insiders Place Their Bets

In related news, insider Michael Bavaro sold 30,996 shares of the company's stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $33.26, for a total transaction of $1,030,926.96. Following the completion of the transaction, the insider now owns 44,974 shares in the company, valued at $1,495,835.24. This represents a 40.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on OPCH. JMP Securities reissued a "market outperform" rating and set a $36.00 price objective on shares of Option Care Health in a report on Tuesday. JPMorgan Chase & Co. lifted their price target on shares of Option Care Health from $40.00 to $41.00 and gave the stock an "overweight" rating in a research note on Thursday, March 6th. Bank of America raised shares of Option Care Health from a "neutral" rating to a "buy" rating and upped their price objective for the company from $26.00 to $33.00 in a research note on Monday, January 13th. Barrington Research reiterated an "outperform" rating and issued a $38.00 target price on shares of Option Care Health in a research report on Monday. Finally, Jefferies Financial Group upgraded shares of Option Care Health from a "hold" rating to a "buy" rating and upped their price target for the company from $26.00 to $35.00 in a research report on Thursday, January 23rd. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $33.75.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.